A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening

Memorial Sloan Kettering Cancer Center (MSK)

Status: Enrolling

Conditions: Pancreas Cancer; Pancreatic Cancer

Treatments: Diagnostic Test: MRI; Diagnostic Test: Endoscopic ultrasound

Study type: Observational

Funder types: Other; NIH

Identifiers

NCT07612046

26-174

Details and patient eligibility

About

The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.

Enrollment: 79 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
• Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
• Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
• Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+

For this pilot MRP study, we will additionally apply the following Criteria:

• Consents to follow-up contact
• US residents
• Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)
• No metallic artifacts covering the pancreas on prior MRCP
• Scheduled for endoscopic ultrasound
• No new contraindications for MRI (e.g. new MR unsafe device)
• No history of claustrophobia or use of anxiolytic on prior MRI
• No history of abdominal surgery that may affect interpretation of either EUS or MR
• No medical conditions that confers increased and/or unacceptable risk for anesthesia

We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in ~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.

• Documentation of Disease

  o No pathologic confirmation of disease is necessary

• Definition of Disease N/A

• Not Pregnant and Not Nursing

• Required Organ Function N/A

Exclusion criteria

-

Trial design

79 participants in 1 patient group

Participants at high risk for pancreas ductal adenocarcinoma

Description:

Participants will be high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry

Treatment:

Diagnostic Test: Endoscopic ultrasound

Diagnostic Test: MRI